Advanced Therapy Medicinal Products (ATMPs) are redefining what is possible in modern medicine, offering the potential for long-term or even curative treatments for patients with serious and often life-threatening conditions. Yet their unique clinical and economic characteristics also present new challenges for pricing, reimbursement and patient access.

This report explores how innovative contracting arrangements, including outcomes-based agreements and staged payment models, are helping to address these challenges across Europe. Drawing on interviews and workshops with manufacturers responsible for bringing ATMPs to market, it captures practical experience of negotiating and implementing innovative agreements with national payers. 

Rather than focusing solely on theory, the paper examines what has worked in practice, where implementation remains difficult and how greater collaboration between manufacturers, payers and healthcare systems could improve future access. It discusses themes including data collection, registry infrastructure, evidence generation, stakeholder alignment and the importance of building trust across the reimbursement pathway. 

As more transformative therapies enter clinical practice, healthcare systems will increasingly need reimbursement approaches capable of accommodating uncertainty while ensuring timely patient access. This report offers practical lessons from organisations already navigating these complex challenges.

Whether you work in market access, pricing, health technology assessment or policy, the report provides valuable insights into the evolving role of innovative contracting and the opportunities to strengthen reimbursement pathways for advanced therapies.

Download the paper to discover the latest learnings from manufacturers and explore practical recommendations for improving ATMP access across Europe.